Çakır Sezin Doğan, Yerli Mustafa, Sonmez Mesut, Adas Mine
Department of Endocrinology and Metabolism Disease, University of Health Sciences, Prof. Dr. Cemil Tascıoglu City Hospital, Istanbul, Turkey.
Department of Orthopedics and Traumatology, University of Healthy Sciences, Prof.Dr. Cemil Tascıoglu City Hospital, Istanbul, Turkey.
Arch Osteoporos. 2025 Jul 16;20(1):97. doi: 10.1007/s11657-025-01584-7.
This study investigates the osteoporosis treatment gap and mortality following hip fractures in Turkey. We found that 83.1% of patients did not receive post-fracture osteoporosis treatment, with a 1-year mortality rate of 37%. Prior treatment, younger age, and parenteral medications were significant predictors of treatment adherence. These findings highlight the urgent need to address treatment gaps and improve patient outcomes.
This study aimed to evaluate the osteoporosis treatment gap, mortality rates, and predictors of mortality in hip fracture patients in a tertiary center in Turkey.
A retrospective analysis was conducted of 552 patients aged over 50 years who were hospitalized for hip fractures at Prof. Dr. Cemil Taşcıoglu City Hospital between January 2015 and November 2022. Data were collected from electronic medical records, including pre- and post-fracture osteoporosis treatment, treatment initiation times, bone mineral density (BMD) tests, and patient outcomes.
The mean age of the cohort was 80.2 years, with a predominance of female patients (65.1%). Prior to the fracture, 90.8% of patients had not received osteoporosis treatment. After the fracture, 83.1% of patients did not receive any osteoporosis medications. Of those treated, 45 patients (8.6%) started treatment within 3 months. The 1-year mortality rate was 37%, with significant predictors including age, male gender, lack of prior osteoporosis treatment, delayed treatment initiation, and short treatment duration. Only 5.6% of patients had a BMD test within the first year after the fracture, which was associated with improved treatment adherence and lower mortality.
The study highlights a significant treatment gap for osteoporosis in hip fracture patients in Turkey. Prior treatment history, younger age, and use of parenteral therapies were strong predictors of adherence to post-fracture osteoporosis treatment. These findings emphasize the need for improved healthcare provider awareness, better treatment initiation protocols, and the implementation of Fracture Liaison Services.
本研究调查了土耳其髋部骨折后的骨质疏松症治疗缺口及死亡率。我们发现，83.1%的患者未接受骨折后骨质疏松症治疗，1年死亡率为37%。先前的治疗、较年轻的年龄以及肠胃外用药是治疗依从性的重要预测因素。这些发现凸显了解决治疗缺口并改善患者预后的迫切需求。
本研究旨在评估土耳其一家三级中心髋部骨折患者的骨质疏松症治疗缺口、死亡率及死亡预测因素。
对2015年1月至2022年11月期间在Cemil Taşcıoglu市教授医院因髋部骨折住院的552名50岁以上患者进行回顾性分析。数据从电子病历中收集，包括骨折前后的骨质疏松症治疗、治疗开始时间、骨密度（BMD）测试及患者预后。
该队列的平均年龄为80.2岁，女性患者占多数（65.1%）。骨折前，90.8%的患者未接受骨质疏松症治疗。骨折后，83.1%的患者未接受任何骨质疏松症药物治疗。在接受治疗的患者中，45名患者（8.6%）在3个月内开始治疗。1年死亡率为37%，重要预测因素包括年龄、男性性别、缺乏先前的骨质疏松症治疗、治疗开始延迟及治疗持续时间短。骨折后第一年内仅有5.6%的患者进行了骨密度测试，这与更好的治疗依从性及更低的死亡率相关。
该研究凸显了土耳其髋部骨折患者骨质疏松症治疗方面存在的显著缺口。先前的治疗史、较年轻的年龄以及肠胃外治疗的使用是骨折后骨质疏松症治疗依从性的有力预测因素。这些发现强调了提高医疗服务提供者的意识、优化治疗开始方案以及实施骨折联络服务的必要性。
